These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 25506285)

  • 1. Renal sympathetic denervation in the treatment of resistant hypertension.
    Sánchez-Álvarez C; González-Vélez M; Stilp E; Ward C; Mena-Hurtado C
    Yale J Biol Med; 2014 Dec; 87(4):527-35. PubMed ID: 25506285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sufficient and Persistent Blood Pressure Reduction in the Final Long-Term Results From SYMPLICITY HTN-Japan　- Safety and Efficacy of Renal Denervation at 3 Years.
    Kario K; Yamamoto E; Tomita H; Okura T; Saito S; Ueno T; Yasuhara D; Shimada K;
    Circ J; 2019 Feb; 83(3):622-629. PubMed ID: 30760655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
    Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
    Epstein M; de Marchena E
    J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.
    Voora R; Hinderliter AL
    Curr Hypertens Rep; 2018 Sep; 20(11):92. PubMed ID: 30194545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.
    Kandzari DE; Bhatt DL; Sobotka PA; O'Neill WW; Esler M; Flack JM; Katzen BT; Leon MB; Massaro JM; Negoita M; Oparil S; Rocha-Singh K; Straley C; Townsend RR; Bakris G
    Clin Cardiol; 2012 Sep; 35(9):528-35. PubMed ID: 22573363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension.
    Schlaich MP
    Am J Hypertens; 2017 Sep; 30(9):847-856. PubMed ID: 28338871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal denervation in the treatment of resistant hypertension: Dead, alive or surviving?
    Al-Fakhouri A; Efeovbokhan N; Nakhla R; Khouzam RN
    Rev Port Cardiol; 2016 Oct; 35(10):531-8. PubMed ID: 27614724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M
    J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal denervation: current state and future perspectives].
    Kara K; Bruck H; Kahlert P; Plicht B; Mahabadi AA; Konorza T; Erbel R
    Herz; 2012 Nov; 37(7):746-53. PubMed ID: 23073661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal denervation for resistant hypertension and beyond.
    Laffin LJ; Bakris GL
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):133-9. PubMed ID: 25704350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant hypertension in 2017.
    Hans S; Reilly JP
    Curr Opin Cardiol; 2017 Jul; 32(4):389-396. PubMed ID: 28505045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Denervation in the treatment of Resistant Hypertension.
    Yap LB; Balachandran K
    Med J Malaysia; 2021 Nov; 76(6):893-897. PubMed ID: 34806679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Italian Society of Interventional Cardiology (GISE) and Italian Society of Arterial Hypertension (SIIA) Consensus document on the role of renal denervation in the management of the difficult to treat hypertension].
    Stabile E; Muiesan ML; Ribichini FL; Sangiorgi G; Taddei S; Versaci F; Villari B; Bacca A; Benedetto D; Fioretti V; Liccardo G; Laurenzano E; Scappaticci M; Saia F; Tarantini G; Grassi G; Esposito G
    G Ital Cardiol (Rome); 2023 Oct; 24(10 Suppl 2):53S-63S. PubMed ID: 37767848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal denervation for resistant hypertension: yes.
    Boschetti E; Alrashdi Y; Schillaci G
    Intern Emerg Med; 2016 Jun; 11(4):491-3. PubMed ID: 26970989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal denervation in the era of HTN-3. Comprehensive review and glimpse into the future.
    Silva JD; Costa M; Gersh BJ; Gonçalves L
    J Am Soc Hypertens; 2016 Aug; 10(8):656-70. PubMed ID: 27319336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catheter-based Renal Sympathetic Denervation - Long-term Symplicity™ Renal Denervation Clinical Evidence, New Data and Future Perspectives.
    Mountfort K; Mahfoud F; Schmieder R; Davies J; Kandzari DE; Weil J; Whitbourn R
    Interv Cardiol; 2013 Aug; 8(2):118-123. PubMed ID: 29588763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Denervation: Where to Now?
    Wimmer NJ; Mauri L
    Curr Cardiol Rep; 2015 Dec; 17(12):116. PubMed ID: 26482759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.